Agonist News and Research

RSS

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that lorcaserin data from the Phase 3 BLOOM-DM trial will be presented in poster sessions at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego, California.

21 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.

17 Jun 2011

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

16 Jun 2011

Mist inhalers increase risk of death in patients with COPD

People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, new Johns Hopkins-led research suggests.

16 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomics Analysis Reveals Elevation of 3-Indoxyl Sulfate in Plasma and Brain during Chemically-induced Acute Kidney Injury in Mice: Investigation of Nicotinic Acid Receptor Agonists", in Toxicology and Applied Pharmacology.

9 Jun 2011

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Men with prostate cancer are at higher risk of developing diabetes or diabetes risk factors if they receive androgen deprivation therapy (ADT) to block the production or action of male hormones that can fuel the growth of this cancer.

6 Jun 2011

New targeted therapy may halt tumor growth in men with advanced prostate cancer

A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 on social impairment in adolescents and adults with fragile X syndrome.

2 Jun 2011

Phadia ImmunoCAP Specific IgE blood test used in largest cross-sectional allergy study

Phadia, the worldwide leader of in vitro allergy diagnostics, is pleased to contribute to the largest cross-sectional allergy study ever conducted through the use of its ImmunoCAP Specific IgE blood test, the market leading in vitro allergy diagnostic test.

27 May 2011

Quest Diagnostics announces results of largest ImmunoCAP cross-sectional allergy study

ImmunoCAP, the worldwide leader of in vitro allergy diagnostics, is pleased to present the results of the largest cross-sectional allergy study ever conducted. The landmark study, announced today by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information, and services, includes test results from over 2 million patients.

From Quest Diagnostics 27 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Synergy expands GC-C agonist technology to lower cholesterol

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical in vitro research demonstrating the inhibition of bile acid uptake by GC-C agonists and that it plans to commence animal studies shortly. Synergy believes this is the first time that GC-C agonists have been shown to potentially lower cholesterol.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

New bronchial thermoplasty long-term safety data in asthma presented at ATS annual meeting

Boston Scientific Corporation today announced long-term safety data from the Research in Severe Asthma (RISA) Trial, which demonstrated the maintenance of stable lung function and the absence of clinical complications over a five-year period in patients with severe refractory asthma treated with its Alair Bronchial Thermoplasty System.

17 May 2011

Agonist News and Research

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Mist inhalers increase risk of death in patients with COPD

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

New targeted therapy may halt tumor growth in men with advanced prostate cancer

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Phadia ImmunoCAP Specific IgE blood test used in largest cross-sectional allergy study

Quest Diagnostics announces results of largest ImmunoCAP cross-sectional allergy study

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Synergy expands GC-C agonist technology to lower cholesterol

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

New bronchial thermoplasty long-term safety data in asthma presented at ATS annual meeting

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News